

Zydus receives USFDA approval for Ramipril Capsules

Ahmedabad, 04 September 2008

Zydus Cadila has received an approval from the USFDA to market Ramipril Capsules in the strengths of 1.25 mg, 2.5 mg, 5 mg and 10 mg. The drug falls in the anti-hypertensive segment. The sales of Ramipril Capsules as per NDC was estimated at USD 1.06 bn.

The group now has 41 approvals and has so far filed 79 ANDAs since the commencement of filing process in FY 2003-04.
